Overview Neoadjuvant Anti-PD1 in HCC Status: Completed Trial end date: 2022-06-30 Target enrollment: Participant gender: Summary This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC. Phase: Phase 2 Details Lead Sponsor: Dr Tan-to CHEUNGTreatments: Nivolumab